
Linghua Wang, M.D., Ph.D.
Department of Genomic Medicine, Division of Cancer Medicine
About Dr. Wang
Dr. Wang is a tenured Associate Professor in the Department of Genomic Medicine. She earned her MD in Medicine and PhD in Cancer Genomics and completed her postdoctoral training at Baylor College of Medicine. Dr. Wang possesses significant expertise in computational biology, immuno-oncology, and cancer immunogenomics. Her group specializes in deep profiling of the cellular and molecular heterogeneity, phenotypic plasticity, and evolution of tumor cells and cells of the tumor microenvironment (TME) using cutting-edge single-cell and spatial omics technologies, coupled with state-of-the-art computation and modeling.
Dr. Wang's research focuses on four main areas: early tumor development, therapy resistance, minimal residual disease (MRD), and metastasis. For early tumor development, she focuses on identifying the earliest events driving tumor progression from precursor diseases, developing models for early prediction of disease progression and outcomes, and identifying therapeutic vulnerabilities and targets for the development of effective interception strategies. Dr. Wang is also interested in studying therapy resistance. Specifically, she seeks to identify tumor cell-intrinsic and microenvironmental factors that influence tumor response to anti-cancer therapies, predict patient response prior to treatment, and identify novel targets for the development of effective combination therapies. With regard to MRD, Dr. Wang characterizes cancer cells as well as the TME that protects and shelters drug-resistant cells. In her work on metastasis, she investigates the cellular and molecular basis of metastases and seeks to understand the cancer evolution, interaction, and adaptation of cancer cells and various types of immune and stromal cells in different local microenvironments at primary and metastatic sites.
Dr. Wang has built an impactful research portfolio and developed a collaborative, team-based approach to tackling cancer. She is currently the Principal Investigator (PI) on an R01 grant and a Multi-PI on a U01 grant from the National Institutes of Health/National Cancer Institute (NIH/NCI). She also serves as the PI/Multi-PI on two Individual Investigator Research Awards (IIRA) from the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Wang has received the Sabin Fellow Award, two SPORE Career Enhancement Program Awards, and multiple Institutional Research Grant Awards. She is the site Leader of Data Science for the Pancreatic and Ovarian Cancer Programs funded by Break Through Cancer (BTC), and is a joint leader of the BTC Data Science Team, the Data Analysis and Visualization Unit of a U24 grant from NIH/NCI, and the MD Anderson Cancer Moon Shot Multiple Myeloma Program. Additionally, Dr. Wang is key personnel in several other grants from NIH/NCI (e.g., R01, SPORE), CPRIT, and the Department of Defense (DoD).
Dr. Wang has a distinguished record of research productivity, having authored ~100 publications. As the first, senior, and/or corresponding author, she has published in high-impact journals such as Nature (2014, 2020), Nature Medicine (2020, 2021), Cancer Discovery (2021, 2022a, 2022b), Blood Cancer Discovery (2022), Lancet Oncology (2022), Nature Genetics (2015), Gut (2019, 2020), Nature Communications (2021-2022, n=5), Science Translational Medicine (2019), Clinical Cancer Research (2019), Cell Reports (2018a, 2018b), Genome Research (2012, 2013), Leukemia (2014a, 2014b), among many others. Dr. Wang is a recognized investigator in her field with a proven track record. She has been invited to serve on multiple grant review panels for NIH/NCI and has also served as a session Chair or Co-Chair for major annual meetings such as the AACR Annual Meeting 2022, SITC Annual Meeting 2022, and the ENAR 2023 Spring meeting. Dr. Wang values collaborations and works closely with physician scientists, pathologists, immunologists, biologists, and data scientists to develop effective data science approaches to identify novel targets and biomarkers to better understand, detect, and treat cancer.In the News

Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses

From a small village in China to MD Anderson: Genomic medicine researcher looks to the future of big data in cancer care

2019 Andrew Sabin Family Fellows share passion for Making Cancer History
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Regular Member, The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), Houston, TX
Research Interests
Computational Biology | Immuno-Oncology | Immunogenomics | Single Cell and Spatial Omics | Tumor Heterogeneity | Tumor Microenvironment | Tumor-Immune Interaction
Education & Training
Degree-Granting Education
2011 | The University of Tokyo, Tokyo, JPN, PHD, Cancer Genomics |
2006 | Sun Yat-Sen University, Guangzhou, CHN, MS, Ophthalmology |
2003 | Taishan Medical University, Taian, CHN, MD, Clinical Medicine |
Postgraduate Training
2012-2014 | Postdoctoral Associate, Cancer Genomics, Baylor College of Medicine, Houston, TX |
2007-2008 | Research Fellowship, Cancer Genetics, Nihon University School of Medicine, Tokyo |
Experience & Service
Academic Appointments
Assistant Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Assistant Professor, Baylor College of Medicine, Houston, TX, 2015 - 2017
Instructor, Baylor College of Medicine, Houston, TX, 2014 - 2015
Other Appointments/Responsibilities
MD Anderson Core Facility Oversight Board, University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Member, Allison Institute Advisory Council (AIAC), The James P. Allison Institute (JPAI), University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Member, CCSG Program, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Member, Cancer Biology and Metastasis Program, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Honors & Awards
2022 | Session co-Chair (Bioinformatics and Computational Biology), AACR Annual Meeting 2022 |
2022 | Session co-Chair (Big Data & Bioinformatics), SITC Annual Meeting 2022 |
2022 | Invited Speaker, Frontiers in Cancer Immunotherapy Annual Symposium 2022 |
2022 | Invited Speaker, Single-Cell Cancer Biology Gordon Research Conference 2022 |
2022 | Individual Investigator Research Award (MPI), CPRIT |
2022 | Excellence in Science (Joint team leader), MDACC |
2021 | Women in Science, Women’s History Month, MDACC |
2021 | Institutional Research Grant Award, MDACC |
2021 | Invited Speaker, European Human Genetics Conference, ESHG |
2021 | Excellence in Science (Team leader), MDACC |
2021 | Excellence in Science (Joint team leader), MDACC |
2020 | Ovarian SPORE CEP Award, NIH/NCI |
2020 | Lung SPORE CEP Award, NIH/NCI |
2020 | Individual Investigator Research Award, CPRIT |
2019 | Sabin Fellow Award, Sabin Family Foundation |
2019 | Institutional Research Grant Award, MDACC |
2017 | Invited Speaker, AACR Annual Meeting, AACR |
2016 | Invited Speaker, Human Genome Meeting, HUGO |
2011 | Outstanding Poster Award, The 9th International Workshop on Advanced Genomics |
2010 | Traveling Award, the 6th International Student Research Forum |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov, 2022. e-Pub 2022. PMID: 36098652.
- Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21(1):185, 2022. e-Pub 2022. PMID: 36163179.
- Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140(5):504-515, 2022. PMID: 35512184.
- Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut, 2022. e-Pub 2022. PMID: 36002248.
- Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
- Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov, 2022. e-Pub 2022. PMID: 35687817.
- Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut, 2022. e-Pub 2021. PMID: 33785559.
- Fedoriw A, Shi L, O'Brien S, Smitheman KN, Wang Y, Hou J, Sherk C, Rajapurkar S, Laraio J, Williams LJ, Xu C, Han G, Feng Q, Bedford MT, Wang L, Barbash O, Kruger RG, Hwu P, Mohammad HP, Peng W. Inhibiting Type I arginine methyltransferase activity promotes the T cell mediated antitumor immune response. Cancer Immunol Res, 2022. e-Pub 2022. PMID: 35181787.
- Wang M, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, OK CY, Kanagal-Shamanna R, Hill HA, Yao Y, Liu Y, Hagemeister FB, Westin J, Fowler N, Samaniego F, Steiner R, Chen W, Oriabure O, Moghrabi OB, Navsaria L, Che Y, Li Y, Avellaneda M, Badillo M, Feng L, Nogueras Gonzalez G, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang S, Yin CC, Li S, Patel KM, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, 2022. e-Pub 2022.
- Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, Wang L, Lin Y, Wang Z, Jaffray D, Hazle JD, Macapinlac HA, Wu J, Lu Y. Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma. Clin Nucl Med, 2022. e-Pub 2022. PMID: 35020640.
- Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
- Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol:JCO2101797, 2021. e-Pub 2021. PMID: 34797699.
- Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol, 2021. e-Pub 2021. PMID: 34789422.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA.. Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers 13(21):5301, 2021. e-Pub 2021.
- Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
- Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373(6561):eabj0486, 2021. e-Pub 2021. PMID: 34529467.
- Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, Scott AW, Pizzi MP, Wang Y, Fan Y, Harada K, Jin J, Ma L, Yao X, Shanbhag ND, Gan Q, Roy-Chowdhuri S, Badgwell BD, Wang Z, Wang L, Ajani JA. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res 40(1):207, 2021. e-Pub 2021. PMID: 34162421.
- Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal Single-Cell Profiling Reveals Molecular Heterogeneity and Tumor-Immune Evolution in Refractory Mantle Cell Lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
- Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov, 2021. e-Pub 2021. PMID: 33972311.
- Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan P, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021. e-Pub 2021. PMID: 34041526.
- Bailey CP, Wang R, Figueroa M, Zhang S, Wang, L, Chandra J.. Computational immune infiltration analysis of pediatric high-grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location. Computational and Systems Oncology, 2021. e-Pub 2021.
- Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33809063.
- Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med, 2021. e-Pub 2021. PMID: 33398161.
- Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JJ, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):687, 2021. e-Pub 2021. PMID: 33514726.
- Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol, 2021. e-Pub 2021. PMID: 33491779.
- Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2021. e-Pub 2021. PMID: 33552049.
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
- Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut, 2020. e-Pub 2020. PMID: 33334899.
- Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Piñeyro D, Castro de Moura M, Esteller M, Shen H, Zenklusen JC, Tarnuzzer R, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn EC, Little RF, White J, Malik S, Harris L, Weil C, Chen AP, Karlovich C, Rodgers B, Shankar L, Jacobs P, Nolan T, Hu J, Muzny DM, Doddapaneni H, Korchina V, Gastier-Foster J, Bowen J, Leraas K, Edmondson EF, Doroshow JH, Conley BA, Ivy SP, Staudt LM. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell, 2020. e-Pub 2020. PMID: 33217343.
- Sinjab A, Han G, Wang L, Kadara H. Field Carcinogenesis in Cancer Evolution: What the Cell Is Going On?. Cancer Res 80(22):4888-4891, 2020. e-Pub 2020. PMID: 33023945.
- Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. J Invest Dermatol 140(11):2146-2156.e4, 2020. e-Pub 2020. PMID: 32304704.
- Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, Singh AK, Raman AT, Terranova C, Sarkar S, Orouji E, Amin SB, Sharma S, Williams M, Samant NS, Dhamdhere M, Zheng N, Shah T, Shah A, Axelrad JB, Anvar NE, Lin YH, Jiang S, Chang EQ, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep 33(3):108293, 2020. PMID: 33086062.
- Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, Ajani JA. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33076512.
- Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporiciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol, 2020. e-Pub 2020. PMID: 33388477.
- Bailey CP, Figueroa M, Gangadharan A, Yang Y, Romero MM, Kennis BA, Yadavilli S, Henry V, Collier T, Monje M, Lee DA, Wang L, Nazarian J, Gopalakrishnan V, Zaky W, Becher OJ, Chandra J. Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG). Neuro Oncol 22(9):1302-1314, 2020. e-Pub 2020. PMID: 32166329.
- Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AK. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. iScience 23(7):101289, 2020. e-Pub 2020. PMID: 32623336.
- Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med 12(554), 2020. PMID: 32727914.
- Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
- Lu Y, Wang L, Ajani JA. Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. Clin Nucl Med 45(4):334-335, 2020. e-Pub 2020. PMID: 31977493.
- Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut, 2020. e-Pub 2020. PMID: 32345613.
- Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study. J Natl Cancer Inst, 2020. e-Pub 2020. PMID: 32339229.
- Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
- Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
- ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93, 2020. e-Pub 2020. PMID: 32025007.
- Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
- Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 18(1):141, 2019. e-Pub 2019. PMID: 31601234.
- Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv 3(15):2400-2408, 2019. PMID: 31405950.
- Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, *Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2019. e-Pub 2019. PMID: 31171626.
- Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res 7(6):1025-1035, 2019. e-Pub 2019. PMID: 31043414.
- Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, *Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491), 2019. PMID: 31068440.
- Liu J, Huang Z, Yang L, Wang X, Wang S, Li C, Liu Y, Cheng Y, Wang B, Sang X, He X, Wang C, Liu T, Liu C, Jin L, Liu C, Zhang X, Wang L, Wang Z. Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma. Theranostics 9(16):4764-4778, 2019. e-Pub 2019. PMID: 31367256.
- Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pool Pizzi M, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA. YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer. Clin Cancer Res. e-Pub 2018. PMID: 30563933.
- Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
- Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
- Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, MC3 Working Group, Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 174(4):1034-1035, 2018. PMID: 30096302.
- Shen H, Shih J, Hollern DP, *Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM, Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA. (*as co-first author). Integrated molecular characterization of testicular germ cell tumors. Cell Rep 23(11):3392-3406, 2018. PMID: 29898407.
- Knijnenburg TA, *Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Cancer Genome Atlas Research Network, Monnat RJ, Xiao Y, Wang C. (*as co-first author). Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254.e6, 2018. PMID: 29617664.
- Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. Immunity 48(4):812-830.e14, 2018. e-Pub 2018. PMID: 29628290.
- Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321-337.e10, 2018. PMID: 29625050.
- Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173(2):291-304.e6, 2018. PMID: 29625048.
- Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33(4):676-689.e3, 2018. e-Pub 2018. PMID: 29622463.
- Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23(1):181-193.e7, 2018. PMID: 29617659.
- Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Cancer Genome Atlas Research Network, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep 23(1):172-180.e3, 2018. PMID: 29617658.
- Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. Oncoimmunology 7(8):e1467856, 2018. e-Pub 2018. PMID: 30221071.
- TCGA-HCC group including *Wang L (*as one of the major contributing authors). Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169(7):1327-1341.e23, 2017. PMID: 28622513.
- Goschzik T, Gessi M, Dreschmann V, Gebhardt U, *Wang L, Yamaguchi S, Wheeler DA, Lauriola L, Lau CC, Müller HL, Pietsch T. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. J Neuropathol Exp Neurol. e-Pub 2017. PMID: 28069929.
- Lanikova L, Babosova O, Swierczek S, *Wang L, Wheeler DA, Divoky V, Korinek V, Prchal JT. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera. Blood 128(18):2266-2270, 2016. e-Pub 2016. PMID: 27647865.
- Eckstein OS, *Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE.. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44(8):740-4, 2016. e-Pub 2016. PMID: 27208809.
- *Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, Xi L, Meng Q, Langridge T, Drummond J, Donehower LA, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Duvic M. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47(12):1426-34, 2015. e-Pub 2015. PMID: 26551670.
- Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP, Covington KR, Trevino L, Dewal N, Muzny DM, Doddapaneni H, Hu J, *Wang L, Lupo PJ, Hicks MJ, Bonilla DL, Dwyer KC, Berres ML, Poulikakos PI, Merad M, McClain KL, Wheeler DA, Allen CE, Parsons DW. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007-15, 2014. e-Pub 2014. PMID: 25202140.
- Arai E, Sakamoto H, Ichikawa H, Totsuka H, Chiku S, Gotoh M, Mori T, Nakatani T, Ohnami S, Nakagawa T, Fujimoto H, Wang L, Aburatani H, Yoshida T, Kanai Y. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer 135(6):1330-42, 2014. e-Pub 2014. PMID: 24504440.
- *Wang L, Yamaguchi S, Burstein MD, Terashima K, Chang K, Ng HK, Nakamura H, He Z, Doddapaneni H, Lewis L, Wang M, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adekunle A, Sun J, Qiao Y, Marth G, Muzny DM, Gibbs RA, Leal SM, Wheeler DA, Lau CC. Novel somatic and germline mutations in intracranial germ cell tumours. Nature 511(7508):241-5, 2014. e-Pub 2014. PMID: 24896186.
- *Wang L, Swierczek SI, Drummond J, Hickman K, Kim SJ, Walker K, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28(4):935-8, 2014. e-Pub 2014. PMID: 24413320.
- *Wang L, Swierczek SI, Lanikova L, Kim SJ, Hickman K, Walker K, Wang K, Drummond J, Doddapaneni H, Reid JG, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. Leukemia 28(4):938-41, 2014. e-Pub 2014. PMID: 24463469.
- Ikeda Y, Oda K, Nakagawa S, Murayama-Hosokawa S, Yamamoto S, Ishikawa S, Wang L, Takazawa Y, Maeda D, Wada-Hiraike O, Kawana K, Fukayama M, Aburatani H, Yano T, Kozuma S, Taketani Y. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. Int J Gynecol Cancer 22(5):725-31, 2012. PMID: 22635024.
- *Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Saiura A, Hirono S, Yamaue H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Ueda H, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 22(2):208-19, 2012. e-Pub 2011. PMID: 22156295.
- Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S, Sonoda K, Totsuka H, Shirakihara T, Sakamoto H, *Wang L, Ojima H, Shimada K, Kosuge T, Okusaka T, Kato K, Kusuda J, Yoshida T, Aburatani H, Shibata T. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43(5):464-9, 2011. e-Pub 2011. PMID: 21499249.
Invited Articles
- Wang L. Developmental Deconvolution Suggests New Tumor Biology and a Tool for Predicting Cancer Origin. Cancer Discov 12(11):2498-2500, 2022. e-Pub 2022. PMID: 36321308.
- Anderson AC, Yanai I, Yates LR, Wang L, Swarbrick A, Sorger P, Santagata S, Fridman WH, Gao Q, Jerby L, Izar B, Shang L, Zhou X. Spatial transcriptomics. Cancer Cell 40(9):895-900, 2022. PMID: 36099884.
- Wang L, Ajani JA. Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. Clin Cancer Res. e-Pub 2019. PMID: 31527165.
- *Wang L, Wheeler DA, Prchal JT.. Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol 44(8):644-52, 2016. e-Pub 2015. PMID: 26646991.
- *Wang L & Wheeler DA.. Genomic sequencing for cancer diagnosis and therapy. Annu Rev Med 65:33-48, 2014. e-Pub 2013. PMID: 24274147.
- Wheeler DA & *Wang L.. From human genome to cancer genome: the first decade. Genome Res 23(7):1054-62, 2013. PMID: 23817046.
- Aburatani H & *Wang L.. Integrated genomic analysis of pancreatic ductal carcinoma. Experimental Medicine 30:33-38, 2012.
Other Articles
- Pravesh Gupta, Minghao Dang, Shivangi Oberai, Mekenzie Peshoff, Nancy Milam, Aml Ahmed, Krishna Bojja, Tuan M. Tran, Kathryn Cox, Huma Shehwana, Carlos Kamiya-Matsuoka, Jianzhuo Li, Joy Gumin, Alicia Goldman, Sameer A. Seth, Atul Maheshwari, Frederick F. Lang, Nicholas E. Navin, Amy B. Heimberger, Karen Clise-Dwyer, Linghua Wang, Krishna P. Bhat Immune landscape of isocitrate dehydrogenase stratified human gliomas. bioRxiv, 2022.
- Guangchun Han, Ansam Sinjab, Warapen Treekitkarnmongkol, Wei Lu, Alejandra G. Serrano, Sharia D. Hernandez, Zahraa Rahal, Xuanye Cao, Enyu Dai, Lorena I. Gomez-Bolanos, Edwin R. Parra, Marcelo Vailati Negrao, Tina Cascone, Boris Sepesi, Seyed Javad Moghaddam, Jichao Chen, Steven M. Dubinett, Paul Scheet, Junya Fujimoto, Luisa M. Solis, Ignacio I. Wistuba, Christopher S. Stevenson, Avrum E. Spira, Linghua Wang, Humam Kadara An atlas of epithelial cell states and plasticity in lung adenocarcinoma. bioRxiv, 2022.
- Xiuning Le, Minghao Dang, VenkateshL. Hegde, Bo Jiang, Ravaen Slay, Weihong Xiao, Keiko Akagi, Joseph Fresquez, Kathrina L. Marcelo, Qianyun Luo, Pragya Sinha, Ananta V. Yanamandra, JoeDan Dunn, Diana Bell, Michelle Williams, Edwin Parra, Ryan Goepfert, Stephen H. Lai, Neil Gross, Amit Agrawal, Alexandre Reuben, Jeffrey Myers, Michael A. Curran, K. Jagannadha Sastry, *Linghua Wang, *Maura L. Gillison TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas. medRxiv.
- Guangchun Han, Qing Deng, Enyu Dai, Minghao Dang, John Ma, Haopeng Yang, Olga Kudryashova, Mark Meerson, Sergey Isaev, Nikita Kotlov, Krystle Nomie, Alexander Bagaev, Simrit Parmar, Fredrick Hagemeister, Sairah Ahmed, Swami Iyer, Filepe Samaniego, Raphael Steiner, Luis Fayad, Hun Lee, Nathan Fowler, Francisco Vega, Christopher R. Flowers, Paolo Strati, Jason R. Westin, Sattva S. Neelapu, Loretta J. Nastoupil, *Linghua Wang & *Michael R. Green Immune microenvironment subtypes and association with tumor cell mutations and antigen expression in follicular lymphoma. bioRxiv.
- Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, Wang M, Ajani J, Futreal A, Wang L iTALK: an R Package to Characterize and Illustrate Intercellular Communication. BioRxiv, 2020.
Grant & Contract Support
Title: | B-Cell Lymphoma Moon Shot Program |
Funding Source: | The University of Texas M.D. Anderson Cancer Center |
Role: | Co-Investigator |
Title: | High-Risk Multiple Myeloma Moon Shot Pilot Program |
Funding Source: | The University of Texas M.D. Anderson Cancer Center |
Role: | Co-Program Leader |
Title: | A biomarker-based, combination therapy with immune checkpoint blockade and pemetrexed for MTAP-deficient metastatic bladder cancer |
Funding Source: | Doris Duke Charitable Foundation |
Role: | Co-Investigator |
Title: | Targeting Tim-3 as a Novel Therapeutic Strategy for Advanced Gastric Cancer with Peritoneal Metastases |
Funding Source: | Andrew Sabin Family Foundation |
Role: | Principal Investigator |
Title: | Dissecting the Multicellular Ecosystem of Metastatic Gastric Adenocarcinoma by Longitudinal Single Cell Sequencing of Malignant Ascites Cells and PBMCs with Primary and Normal Gastric Tissue as control |
Funding Source: | MDACC-IRG |
Role: | Principal Investigator |
Title: | Epithelial memory of resolved inflammation as a driver of pancreatic cancer progression |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | Ovarian SPORE CEP Award |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Lung SPORE CEP |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Predicting Response and Improving Efficacy of CAR T-cell Therapy in DLBCL |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Principal Investigator |
Title: | Contribution of tumor heterogeneity in eliciting response to the immune system |
Funding Source: | The V Foundation |
Role: | Co-Investigator |
Title: | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Analysis of the genetic landscape in the evolution of oligometastatic prostate cancer through peripheral bioanalytes |
Funding Source: | Department of Defense (DOD) |
Role: | Collaborator |
Title: | Identifying the determinants of clinical responses to PARP inhibitors in ovarian cancer immunotherapy |
Funding Source: | Department of Defense (DOD) |
Role: | Co-Investigator |
Title: | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Evolution of small-cell lung cancer from the normal airway |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | Single-Cell Decoding of Spatiotemporal and Ecological Evolution in Early-Stage KRAS-Mutant Lung Cancer |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Principal Investigator |
Title: | Translating Novel Discoveries in Gastric Adenocarcinoma Biology into Therapeutic Advances |
Funding Source: | Department of Defense (DOD) |
Role: | Co-Investigator |
Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Minimal Residual Disease, Ovarian Cancer Breakthrough Program |
Funding Source: | Break Through Cancer |
Role: | site Lead of Data Science |
Title: | Conquering KRAS, Pancreatic Cancer Breakthrough Program |
Funding Source: | Break Through Cancer |
Role: | site Lead of Data Science |
Title: | Minimal Original Disease, Ovarian Cancer Breakthrough Program |
Funding Source: | Break Through Cancer |
Role: | Co-Investigator |
Title: | PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education) |
Funding Source: | NIH/NCI |
Role: | Lead of the Data Analysis and Data Visualization Unit |
Title: | Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | BTC Data Science Hub |
Funding Source: | Break Through Cancer |
Role: | Co-Leader of Data Science |